3 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
CKD-related outcomes were more strongly associated with the burden of cardiometabolic abnormalities than with hepatic steatosis itself, and these associations were consistent in individuals with and without SLD.
Fibrosis improvement in MASH is attainable by available drugs with further promise from emerging therapies, and a rich therapeutic pipeline with the promise of combination regimens and increased focus non-invasive endpoints suggests that the future looks bright for patients living with fibrotic MASH.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
